Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 58

1.

Novel strategy of ovarian cancer implantation: Pre-invasive growth of fibrin-anchored cells with neovascularization.

Matsuoka A, Mizumoto Y, Ono M, Kagami K, Obata T, Terakawa J, Maida Y, Nakamura M, Daikoku T, Fujiwara H.

Cancer Sci. 2019 Aug;110(8):2658-2666. doi: 10.1111/cas.14098. Epub 2019 Jul 9.

2.

Eribulin penetrates brain tumor tissue and prolongs survival of mice harboring intracerebral glioblastoma xenografts.

Takahashi M, Miki S, Fujimoto K, Fukuoka K, Matsushita Y, Maida Y, Yasukawa M, Hayashi M, Shinkyo R, Kikuchi K, Mukasa A, Nishikawa R, Tamura K, Narita Y, Hamada A, Masutomi K, Ichimura K.

Cancer Sci. 2019 Jul;110(7):2247-2257. doi: 10.1111/cas.14067. Epub 2019 Jun 10.

3.

Factors Regulating Human Extravillous Trophoblast Invasion: Chemokine-peptidase and CD9-integrin Systems.

Fujiwara H, Matsumoto H, Sato Y, Horie A, Ono M, Nakamura M, Mizumoto Y, Kagami K, Fujiwara T, Hattori A, Maida Y, Daikoku T, Imakawa K, Araki Y.

Curr Pharm Biotechnol. 2018;19(10):764-770. doi: 10.2174/1389201019666181029164906. Review.

PMID:
30378495
4.

Semi-quantitative Detection of RNA-dependent RNA Polymerase Activity of Human Telomerase Reverse Transcriptase Protein.

Maida Y, Yasukawa M, Ghilotti M, Ando Y, Masutomi K.

J Vis Exp. 2018 Jun 12;(136). doi: 10.3791/57021.

5.

Driving frequency optimization of a piezoelectric transducer and the power supply development.

Dong X, Yuan T, Hu M, Shekhani H, Maida Y, Tou T, Uchino K.

Rev Sci Instrum. 2016 Oct;87(10):105003.

PMID:
27802753
6.

De Novo RNA Synthesis by RNA-Dependent RNA Polymerase Activity of Telomerase Reverse Transcriptase.

Maida Y, Yasukawa M, Masutomi K.

Mol Cell Biol. 2016 Mar 31;36(8):1248-59. doi: 10.1128/MCB.01021-15. Print 2016 Apr.

7.

Exosomal transfer of functional small RNAs mediates cancer-stroma communication in human endometrium.

Maida Y, Takakura M, Nishiuchi T, Yoshimoto T, Kyo S.

Cancer Med. 2016 Feb;5(2):304-14. doi: 10.1002/cam4.545. Epub 2015 Dec 24.

8.

Telomerase reverse transcriptase moonlights: Therapeutic targets beyond telomerase.

Maida Y, Masutomi K.

Cancer Sci. 2015 Nov;106(11):1486-92. doi: 10.1111/cas.12806. Epub 2015 Oct 21. Review.

9.

Telomerase reverse transcriptase regulates microRNAs.

Lassmann T, Maida Y, Tomaru Y, Yasukawa M, Ando Y, Kojima M, Kasim V, Simon C, Daub CO, Carninci P, Hayashizaki Y, Masutomi K.

Int J Mol Sci. 2015 Jan 6;16(1):1192-208. doi: 10.3390/ijms16011192.

10.

Eribulin mesylate targets human telomerase reverse transcriptase in ovarian cancer cells.

Yamaguchi S, Maida Y, Yasukawa M, Kato T, Yoshida M, Masutomi K.

PLoS One. 2014 Nov 6;9(11):e112438. doi: 10.1371/journal.pone.0112438. eCollection 2014.

11.

Concurrent estrogen action was essential for maximal progestin effect in oral contraceptives.

Bono Y, Kyo S, Kiyono T, Mizumoto Y, Nakamura M, Maida Y, Takakura M, Fujiwara H.

Fertil Steril. 2014 May;101(5):1337-43. doi: 10.1016/j.fertnstert.2014.02.005. Epub 2014 Mar 19.

PMID:
24656887
12.

Involvement of telomerase reverse transcriptase in heterochromatin maintenance.

Maida Y, Yasukawa M, Okamoto N, Ohka S, Kinoshita K, Totoki Y, Ito TK, Minamino T, Nakamura H, Yamaguchi S, Shibata T, Masutomi K.

Mol Cell Biol. 2014 May;34(9):1576-93. doi: 10.1128/MCB.00093-14. Epub 2014 Feb 18.

13.

Molecular characterization of CD133+ cancer stem-like cells in endometrial cancer.

Nakamura M, Zhang X, Mizumoto Y, Maida Y, Bono Y, Takakura M, Kyo S.

Int J Oncol. 2014 Mar;44(3):669-77. doi: 10.3892/ijo.2013.2230. Epub 2013 Dec 23.

PMID:
24366104
14.

Imatinib sensitizes endometrial cancer cells to cisplatin by targeting CD117-positive growth-competent cells.

Zhang X, Kyo S, Nakamura M, Mizumoto Y, Maida Y, Bono Y, Takakura M, Fujiwara H.

Cancer Lett. 2014 Apr 1;345(1):106-14. doi: 10.1016/j.canlet.2013.11.020. Epub 2013 Dec 11.

PMID:
24333732
15.

Off-target effect of endogenous siRNA derived from RMRP in human cells.

Maida Y, Kyo S, Lassmann T, Hayashizaki Y, Masutomi K.

Int J Mol Sci. 2013 Apr 29;14(5):9305-18. doi: 10.3390/ijms14059305.

16.

The PRB-dependent FOXO1/IGFBP-1 axis is essential for progestin to inhibit endometrial epithelial growth.

Nakamura M, Takakura M, Fujii R, Maida Y, Bono Y, Mizumoto Y, Zhang X, Kiyono T, Kyo S.

Cancer Lett. 2013 Aug 9;336(1):68-75. doi: 10.1016/j.canlet.2013.04.010. Epub 2013 Apr 18.

PMID:
23603247
17.

Circulating tumour cells detected by a novel adenovirus-mediated system may be a potent therapeutic marker in gynaecological cancers.

Takakura M, Kyo S, Nakamura M, Maida Y, Mizumoto Y, Bono Y, Zhang X, Hashimoto Y, Urata Y, Fujiwara T, Inoue M.

Br J Cancer. 2012 Jul 24;107(3):448-54. doi: 10.1038/bjc.2012.276. Epub 2012 Jun 26.

18.

Creation of immortalised epithelial cells from ovarian endometrioma.

Bono Y, Kyo S, Takakura M, Maida Y, Mizumoto Y, Nakamura M, Nomura K, Kiyono T, Inoue M.

Br J Cancer. 2012 Mar 13;106(6):1205-13. doi: 10.1038/bjc.2012.26. Epub 2012 Feb 21.

19.

Maintenance of tumor initiating cells of defined genetic composition by nucleostemin.

Okamoto N, Yasukawa M, Nguyen C, Kasim V, Maida Y, Possemato R, Shibata T, Ligon KL, Fukami K, Hahn WC, Masutomi K.

Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20388-93. doi: 10.1073/pnas.1015171108. Epub 2011 Jul 5.

20.

Stem cells in endometrium and endometrial cancer: accumulating evidence and unresolved questions.

Kyo S, Maida Y, Inoue M.

Cancer Lett. 2011 Sep 28;308(2):123-33. doi: 10.1016/j.canlet.2011.05.015. Epub 2011 Jun 17. Review.

PMID:
21683518
21.

Comparison of telomere length and association with progenitor cell markers in lacrimal gland between Sjögren syndrome and non-Sjögren syndrome dry eye patients.

Kawashima M, Kawakita T, Maida Y, Kamoi M, Ogawa Y, Shimmura S, Masutomi K, Tsubota K.

Mol Vis. 2011;17:1397-404. Epub 2011 May 27.

22.

Activation of NF-kappaB is a novel target of KRAS-induced endometrial carcinogenesis.

Mizumoto Y, Kyo S, Kiyono T, Takakura M, Nakamura M, Maida Y, Mori N, Bono Y, Sakurai H, Inoue M.

Clin Cancer Res. 2011 Mar 15;17(6):1341-50. doi: 10.1158/1078-0432.CCR-10-2291.

23.

Two-step cleavage of hairpin RNA with 5' overhangs by human DICER.

Ando Y, Maida Y, Morinaga A, Burroughs AM, Kimura R, Chiba J, Suzuki H, Masutomi K, Hayashizaki Y.

BMC Mol Biol. 2011 Feb 9;12:6. doi: 10.1186/1471-2199-12-6.

24.

RNA-dependent RNA polymerases in RNA silencing.

Maida Y, Masutomi K.

Biol Chem. 2011 Apr;392(4):299-304. doi: 10.1515/BC.2011.035. Epub 2011 Feb 7. Review.

PMID:
21294682
25.

Forkhead transcription factor FOXO1 is a direct target of progestin to inhibit endometrial epithelial cell growth.

Kyo S, Sakaguchi J, Kiyono T, Shimizu Y, Maida Y, Mizumoto Y, Mori N, Nakamura M, Takakura M, Miyake K, Sakamoto M, Inoue M.

Clin Cancer Res. 2011 Feb 1;17(3):525-37. doi: 10.1158/1078-0432.CCR-10-1287. Epub 2010 Dec 3.

26.

Prognostic impact of CD133 expression as a tumor-initiating cell marker in endometrial cancer.

Nakamura M, Kyo S, Zhang B, Zhang X, Mizumoto Y, Takakura M, Maida Y, Mori N, Hashimoto M, Ohno S, Inoue M.

Hum Pathol. 2010 Nov;41(11):1516-29. doi: 10.1016/j.humpath.2010.05.006. Epub 2010 Aug 30.

PMID:
20800872
27.

Expression of HER-2 affects patient survival and paclitaxel sensitivity in endometrial cancer.

Mori N, Kyo S, Nakamura M, Hashimoto M, Maida Y, Mizumoto Y, Takakura M, Ohno S, Kiyono T, Inoue M.

Br J Cancer. 2010 Sep 7;103(6):889-98. doi: 10.1038/sj.bjc.6605805. Epub 2010 Jul 27.

28.

Bone marrow-derived cells from male donors can compose endometrial glands in female transplant recipients.

Ikoma T, Kyo S, Maida Y, Ozaki S, Takakura M, Nakao S, Inoue M.

Am J Obstet Gynecol. 2009 Dec;201(6):608.e1-8. doi: 10.1016/j.ajog.2009.07.026. Epub 2009 Oct 3.

PMID:
19800602
29.

An RNA-dependent RNA polymerase formed by TERT and the RMRP RNA.

Maida Y, Yasukawa M, Furuuchi M, Lassmann T, Possemato R, Okamoto N, Kasim V, Hayashizaki Y, Hahn WC, Masutomi K.

Nature. 2009 Sep 10;461(7261):230-5. doi: 10.1038/nature08283. Epub 2009 Aug 23.

30.

Diagnostic potential and limitation of imaging cancer cells in cytological samples using telomerase-specific replicative adenovirus.

Maida Y, Kyo S, Sakaguchi J, Mizumoto Y, Hashimoto M, Mori N, Ikoma T, Nakamura M, Takakura M, Urata Y, Fujiwara T, Inoue M.

Int J Oncol. 2009 Jun;34(6):1549-56.

PMID:
19424572
31.

Role of menin in the regulation of telomerase activity in normal and cancer cells.

Hashimoto M, Kyo S, Hua X, Tahara H, Nakajima M, Takakura M, Sakaguchi J, Maida Y, Nakamura M, Ikoma T, Mizumoto Y, Inoue M.

Int J Oncol. 2008 Aug;33(2):333-40.

PMID:
18636154
32.

Concomitant activation of AKT with extracellular-regulated kinase 1/2 occurs independently of PTEN or PIK3CA mutations in endometrial cancer and may be associated with favorable prognosiss.

Mori N, Kyo S, Sakaguchi J, Mizumoto Y, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.

Cancer Sci. 2007 Dec;98(12):1881-8. Epub 2007 Oct 9.

33.

Analysis of outcome of Stage I-III endometrial cancer treated with systematic operation omitting paraaortic lymphadenectomy.

Kyo S, Hashimoto M, Maida Y, Mizumoto Y, Nakamura M, Takakura M, Inoue M.

Eur J Gynaecol Oncol. 2007;28(3):170-3.

PMID:
17624080
34.

Activation of ERK1/2 occurs independently of KRAS or BRAF status in endometrial cancer and is associated with favorable prognosis.

Mizumoto Y, Kyo S, Mori N, Sakaguchi J, Ohno S, Maida Y, Hashimoto M, Takakura M, Inoue M.

Cancer Sci. 2007 May;98(5):652-8. Epub 2007 Mar 27.

35.

Distinct telomere length regulation in premalignant cervical and endometrial lesions: implications for the roles of telomeres in uterine carcinogenesis.

Maida Y, Kyo S, Forsyth NR, Takakura M, Sakaguchi J, Mizumoto Y, Hashimoto M, Nakamura M, Nakao S, Inoue M.

J Pathol. 2006 Oct;210(2):214-23.

PMID:
16909412
36.

Creation of tumorigenic human endometrial epithelial cells with intact chromosomes by introducing defined genetic elements.

Mizumoto Y, Kyo S, Ohno S, Hashimoto M, Nakamura M, Maida Y, Sakaguchi J, Takakura M, Inoue M, Kiyono T.

Oncogene. 2006 Sep 14;25(41):5673-82. Epub 2006 Apr 24.

PMID:
16636665
37.

High Twist expression is involved in infiltrative endometrial cancer and affects patient survival.

Kyo S, Sakaguchi J, Ohno S, Mizumoto Y, Maida Y, Hashimoto M, Nakamura M, Takakura M, Nakajima M, Masutomi K, Inoue M.

Hum Pathol. 2006 Apr;37(4):431-8.

PMID:
16564917
38.

[CA72-4 (TAG-72)].

Maida Y, Kyo S, Inoue M.

Nihon Rinsho. 2005 Aug;63 Suppl 8:672-4. Review. Japanese. No abstract available.

PMID:
16149608
39.

Efficient inhibition of human telomerase reverse transcriptase expression by RNA interference sensitizes cancer cells to ionizing radiation and chemotherapy.

Nakamura M, Masutomi K, Kyo S, Hashimoto M, Maida Y, Kanaya T, Tanaka M, Hahn WC, Inoue M.

Hum Gene Ther. 2005 Jul;16(7):859-68.

PMID:
16000067
40.

Aberrant expression and mutations of TGF-beta receptor type II gene in endometrial cancer.

Sakaguchi J, Kyo S, Kanaya T, Maida Y, Hashimoto M, Nakamura M, Yamada K, Inoue M.

Gynecol Oncol. 2005 Sep;98(3):427-33.

PMID:
15993480
41.

Association of mismatch repair deficiency with PTEN frameshift mutations in endometrial cancers and the precursors in a Japanese population.

Kanaya T, Kyo S, Sakaguchi J, Maida Y, Nakamura M, Takakura M, Hashimoto M, Mizumoto Y, Inoue M.

Am J Clin Pathol. 2005 Jul;124(1):89-96.

PMID:
15923161
42.

Pharmacokinetics of paclitaxel in ovarian cancer patients and genetic polymorphisms of CYP2C8, CYP3A4, and MDR1.

Nakajima M, Fujiki Y, Kyo S, Kanaya T, Nakamura M, Maida Y, Tanaka M, Inoue M, Yokoi T.

J Clin Pharmacol. 2005 Jun;45(6):674-82.

PMID:
15901749
43.

Analysis of telomeric single-strand overhang length in human endometrial cancers.

Hashimoto M, Kyo S, Masutomi K, Maida Y, Sakaguchi J, Mizumoto Y, Nakamura M, Hahn WC, Inoue M.

FEBS Lett. 2005 May 23;579(13):2959-64.

44.

[Genetic diagnosis of endometrial cancer].

Kanaya T, Kyo S, Maida Y, Inoue M.

Nihon Rinsho. 2004 Oct;62 Suppl 10:295-8. Review. Japanese. No abstract available.

PMID:
15535254
45.

Analysis of telomerase activity and telomere length in bone and soft tissue tumors.

Terasaki T, Kyo S, Takakura M, Maida Y, Tsuchiya H, Tomita K, Inoue M.

Oncol Rep. 2004 Jun;11(6):1307-11.

PMID:
15138570
46.

HIF-1-mediated activation of telomerase in cervical cancer cells.

Yatabe N, Kyo S, Maida Y, Nishi H, Nakamura M, Kanaya T, Tanaka M, Isaka K, Ogawa S, Inoue M.

Oncogene. 2004 Apr 29;23(20):3708-15.

PMID:
15048086
47.

hTERT-promoter-based tumor-specific expression of MCP-1 effectively sensitizes cervical cancer cells to a low dose of cisplatin.

Nakamura M, Kyo S, Kanaya T, Yatabe N, Maida Y, Tanaka M, Ishida Y, Fujii C, Kondo T, Inoue M, Mukaida N.

Cancer Gene Ther. 2004 Jan;11(1):1-7.

PMID:
14681721
48.

Successful immortalization of endometrial glandular cells with normal structural and functional characteristics.

Kyo S, Nakamura M, Kiyono T, Maida Y, Kanaya T, Tanaka M, Yatabe N, Inoue M.

Am J Pathol. 2003 Dec;163(6):2259-69.

49.

Significance of immunological detection of human telomerase reverse transcriptase: re-evaluation of expression and localization of human telomerase reverse transcriptase.

Kyo S, Masutomi K, Maida Y, Kanaya T, Yatabe N, Nakamura M, Tanaka M, Takarada M, Sugawara I, Murakami S, Taira T, Inoue M.

Am J Pathol. 2003 Sep;163(3):859-67.

50.

Evidence of the monoclonal composition of human endometrial epithelial glands and mosaic pattern of clonal distribution in luminal epithelium.

Tanaka M, Kyo S, Kanaya T, Yatabe N, Nakamura M, Maida Y, Okabe M, Inoue M.

Am J Pathol. 2003 Jul;163(1):295-301.

Supplemental Content

Support Center